Description

The Chemi-Verse™ FYN Kinase Assay Kit is designed to measure FYN (FYN proto-oncogene, Src family tyrosine kinase) tyrosine kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified FYN, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Background

FYN, also known as p59-FYN, SLK, SYN, is a member of the SFK (Src family of kinase) non-receptor tyrosine kinase protein family. It is involved in cell growth, adhesion and cytoskeletal remodeling, axon guidance and synaptic function, platelet activation and T-cell receptor signaling. Its levels are regulated by miRNA, transcription factors such as STAT5 (signal transducer and activator of transcription 5) and RUNX2 (runt-related transcription factor 2), and the Cbl (Casitas B-lineage lymphoma) ubiquitin E3 ligase. It is normally a tumor suppressor, but dysfunction can lead to prostate cancer, leukemia, pancreatic cancer, breast cancer and others. Downregulation of miR-153-3p levels leads to increased levels of FYN in ESCC (esophageal squamous cell carcinoma). On the other hand, miR-381 downregulates FYN and can make breast cancer cells more susceptible to doxorubicin. FYN activity is regulated by multiple upstream proteins, including CD16 and KRAS (Kirsten rat sarcoma), and in turn can regulate many substrates that are involved in cell growth. This protein is also involved in the development of drug resistance, as in the resistance to imatinib in leukemia. Several inhibitors have been developed to target FYN, with saracatinib being in phase II clinical trials for prostate cancer. Inhibition of FYN is of interest in Alzheimer's disease (AD), as this protein acts downstream on the pathological pathway of amyloid beta (Aβ) that leads to the disease. Oligomeric Aβ binds to PrPC (cellular prion protein) and activates a pathway dependent on mGluR5 (metabotropic glutamate receptor 5) and FYN. Thus, targeting FYN with saracatinib for the treatment of AD is in clinical trial. These multiple crucial roles make this protein an attractive therapeutic target in cancer and AD.

Applications

Study enzyme kinetics and screen small molecule inhibitors for drug discovery and high throughput screening (HTS) applications.

Supplied Materials

Catalog #	Name	Amount	Storage
40433	FYN, FLAG-Tag*	3 µg	-80°C
79334	5x Kinase Buffer 1	1.5 ml	-20°C
79686	500 µM ATP	50 µl	-20°C
40217	PTK Substrate Poly(Glu:Tyr 4:1) (10 mg/ml)	50 µl	-20°C
82545	White 96-well plate	1	Room Temperature

**The concentration of the protein is lot-specific and will be indicated on the tube.*

BPS Bioscience
● bpsbioscience.com ● 858-202-1401 ● support@bpsbioscience.com

Materials Required but Not Supplied

Name	Ordering Information
ADP-Glo™ Kinase Assay	Promega #V6930
DTT (Dithiothreitol), 1M, optional	
Microplate reader capable of reading luminescence	
Adjustable micropipettor and sterile tips	
30°C incubator	

Storage Conditions

This assay kit will perform optimally for up to **6 months** from date of receipt when the materials are stored as directed.

Safety

This product is for research purposes only and not for human or therapeutic use. This product should be considered hazardous and is harmful by inhalation, in contact with skin, eyes, clothing, and if swallowed. If contact occurs, wash thoroughly.

Assay Principle

The **ADP-Glo™ Kinase Assay (Promega #V6930)** quantifies the amount of ADP produced by a kinase upon phosphorylation of a substrate. First, addition of the ADP-Glo™ reagent terminates the reaction and quenches the remaining ATP. Second, the addition of the Kinase Detection reagent converts the produced ADP to ATP. The newly generated ATP is quantified by a luciferase reaction. The luminescent signal correlates with the amount of ADP generated by the kinase and is linear to 1 mM ATP.

Contraindications

The final concentration of DMSO in the assay should not exceed 1%.

Assay Protocol

- All samples and controls should be tested in duplicate.
- The assay should include “Blank”, “Positive Control” and “Test Inhibitor” conditions.
- We recommend maintaining the diluted protein on ice during use.
- For detailed information on protein handling please refer to Protein FAQs (bpsbioscience.com).
- We recommend using Staurosporine (#27002) or Dasatinib (#82560) or Saracatinib (#82561) as internal control. If not running a dose response curve for the control inhibitor, we recommend running the control inhibitor at 0.1X, 1X and 10X the IC_{50} value shown in the validation data below.
- For instructions on how to prepare reagent dilutions please refer to Serial Dilution Protocol (bpsbioscience.com).

1. Thaw **5x Kinase Assay Buffer 1**, **500 µM ATP,** and **PTK substrate Poly(Glu:Tyr 4:1) (10 mg/ml).**

   *Optional: If desired, make **5x Kinase Assay Buffer 1** with 10 mM DTT.*

2. Prepare 3 ml of **1x Kinase Assay Buffer 1** by mixing 600 µl of **5x Kinase Assay Buffer 1** with 2,400 µl of distilled water.

   *Note: Three (3 ml) of **1x Kinase Assay Buffer 1** is sufficient for 100 reactions.*

3. Prepare a **Master Mix** (12.5 µl/well): N wells x (6 µl of 5x Kinase Assay Buffer 1 + 0.5 µl of 500 µM ATP + 0.5 µl of PTK substrate Poly(Glu:Tyr 4:1)(10 mg/ml) + 5.5 µl of distilled water).

4. Add 12.5 µl of Master Mix to every well.

5. Prepare the **Test Inhibitor** (2.5 µl/well): for a titration prepare serial dilutions at concentrations 10-fold higher than the desired final concentrations. The final volume of the reaction is 25 µl.

   5.1 If the Test Inhibitor is water-soluble: Prepare serial dilutions in 1x Kinase Assay Buffer 1, 10-fold more concentrated than the desired final concentrations.

   For the positive and negative controls, use 1x Kinase Assay Buffer 1 (Diluent Solution).

   OR

   5.2 If the Test inhibitor is soluble in DMSO: Prepare the test inhibitor at 100-fold the highest desired concentration in 100% DMSO, then dilute the inhibitor 10-fold in 1x Kinase Assay Buffer 1 to prepare the highest concentration of the 10-fold intermediate dilutions. The concentration of DMSO is now 10%.

   Prepare serial dilutions of the Test Inhibitor at 10-fold the desired final concentrations using 10% DMSO in 1x Kinase Assay Buffer 1 to keep the concentration of DMSO constant.

   For positive and negative controls, prepare 10% DMSO in 1x Kinase Assay Buffer 1 (vol/vol) so that all wells contain the same amount of DMSO (Diluent Solution).

   Note: The final concentration of DMSO should not exceed 1%.

6. Add 2.5 µl of Test Inhibitor to each well labeled “Test Inhibitor”.

7. Add 2.5 µl of Diluent Solution to the “Positive Control" and “Blank” wells.

8. Add 10 µl of 1x Kinase Assay Buffer 1 to the "Blank" wells.

9. Thaw **FYN Kinase** on ice. Briefly spin the tube to recover its full content.

10. Dilute the protein kinase (10 µl/well) to 3 ng/µl with **1x Kinase Assay Buffer 1**.

11. Initiate the reaction by adding 10 µl of diluted kinase to the wells designated “Positive Control” and "Test Inhibitor".

Component	Blank	Positive Control	Test Inhibitor
Master Mix	12.5 µl	12.5 µl	12.5 µl
Test Inhibitor	-	-	2.5 µl
Diluent Solution	2.5 µl	2.5 µl	-
1x Kinase Assay Buffer 1	10 µl	-	-
Diluted FYN (3 ng/µl)	-	10 µl	10 µl
Total	**25 µl**	**25 µl**	**25 µl**

12. Incubate at 30°C for 45 minutes.

13. Thaw the ADP-Glo™ reagent.

14. At the end of the 45 minute reaction, add 25 µl of ADP-Glo™ reagent to each well.

15. Cover the plate with aluminum foil and incubate at Room Temperature (RT) for 45 minutes.

16. Thaw the Kinase Detection Reagent.

17. Add 50 µl of Kinase Detection reagent to each well.

18. Cover the plate with aluminum foil and incubate at RT for another 45 minutes.

19. Immediately read in a luminometer or a microplate reader capable of reading luminescence.

20. The "Blank" value is subtracted from all other readings.

Reading Luminescence

Luminescence is the emission of light resulting from a chemical reaction. The detection of luminescence requires no wavelength selection because the method used is emission photometry and not emission spectrophotometry.

To properly read luminescence, make sure the plate reader is set for LUMINESCENCE mode. Typical integration time is 1 second, delay after plate movement is 100 msec. Do not use a filter when measuring light emission. Typical settings for the Synergy 2 BioTek plate reader: use the "hole" position on the filter wheel; Optics position: Top; Read type: endpoint. Sensitivity may be adjusted based on the luminescence of a control assay without enzyme (typically we set this value as 100).

Example Results



Figure 1: Inhibition of FYN *kinase activity by Dasatinib, Saracatinib or Staurosporine.*
FYN kinase activity was measured in the presence of increasing concentrations of Dasatinib (#82560), Saracatinib (#82561) or Staurosporine (#27002). The "Blank" value was subtracted from all other values. Results are expressed as the percent of control (kinase activity in the absence of inhibitor, set at 100%).

Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com.

Troubleshooting Guide
Visit bpsbioscience.com/assay-kits-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com

References
Nygaard H., 2018 *Biol Psychiatry* 83(4): 369-376.
Feng S. and Fu Y., 2023 *Journal of Translational Medicine* 21:84.

Related Products

Products	*Catalog #*	*Size*
Chemi-Verse™ SRC Kinase Assay Kit	82555	96 reactions
CSK Kinase Assay Kit	78818	96 reactions
Chemi-Verse™ YES1 Kinase Assay Kit	82556	96 reactions
SRC, GST-tag Recombinant	40483	10 µg
SRC, His-Tag Recombinant	40484	10 µg
CSK, GST-His-Th-Tag Recombinant	40410	10 µg

Version 060324